FLAURA2 shows early EGFR ctDNA clearance is prognostic but does not predict benefit from adding chemotherapy to first-line ...

New research indicates that commonly used measures of kidney function largely underestimate the prevalence of chronic kidney disease (CKD) in patients with cancer. The findings will be presented at ...

A study of 1,200 adults with solid tumors presented at ASN Kidney Week 2026 found that creatinine-based and ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today presented new biomarker data from the Phase 3 PROTECT Study providing ...

A BMC Pediatrics study finds that a random forest model combining serum creatinine and cystatin C, further improved by adding ...

Oric Pharmaceuticals (NASDAQ:ORIC) reported updated Phase 1b data for enozertinib in previously untreated patients with ...

Medically reviewed by Matthew Wosnitzer, MD Key Takeaways The main tests for kidney disease are an estimated glomerular filtration rate (eGFR) blood test and a urine albumin-to-creatinine ratio (UACR) ...

Enozertinib shows strong efficacy in advanced NSCLC with EGFR atypical mutations, entering Phase 3 trials in 2027. ORIC ...

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today presented ...

In a 1L EGFR atypical population with more than double the rate of baseline CNS metastases as competitor datasets, enozertinib demonstrates a potential best-in-class 84% confirmed systemic ORR and 70% ...

Phase 3 trials for three different agents show substantial reductions in kidney function decline and other improvements ...

AstraZeneca AZN announced that the FDA has approved its blockbuster rare disease drug, Ultomiris (ravulizumab), for reducing ...